Subvalvular aortic stenosis
disease diseaseOn this page
Summary
Subvalvular aortic stenosis (MONDO:0006987) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | subvalvular aortic stenosis |
| Mondo ID | MONDO:0006987 |
| EFO | EFO:1001199 |
| MeSH | D001020 |
| DOID | DOID:5805 |
| NCIT | C85172 |
| SNOMED CT | 204368006 |
| UMLS | C0340375 |
| MedGen | 90950 |
| GARD | 0005052 |
| MedDRA | 10042431 |
| Is cancer (heuristic) | no |
Data availability: 1 ClinVar variant.
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart valve disorder › aortic valve disorder › aortic valve stenosis › subvalvular aortic stenosis
Related subtypes (3): supravalvular aortic stenosis, congenital aortic valve stenosis, childhood aortic valve stenosis
Subtypes (1): discrete subaortic stenosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
1 retrieved; paginated sample, class counts are floors:
1 uncertain significance
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 180340 | NM_004415.4(DSP):c.2550_2552dup (p.Leu851dup) | DSP | Uncertain significance | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 11 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| DSP | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| DSP | Orphanet:158687 | Lethal acantholytic erosive disorder |
| DSP | Orphanet:2032 | Idiopathic pulmonary fibrosis |
| DSP | Orphanet:293165 | Skin fragility-woolly hair-palmoplantar keratoderma syndrome |
| DSP | Orphanet:293888 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant |
| DSP | Orphanet:293899 | Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant |
| DSP | Orphanet:293910 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant |
| DSP | Orphanet:369992 | Severe dermatitis-multiple allergies-metabolic wasting syndrome |
| DSP | Orphanet:476096 | Erythrokeratodermia-cardiomyopathy syndrome |
| DSP | Orphanet:50942 | Striate palmoplantar keratoderma |
| DSP | Orphanet:65282 | Carvajal syndrome |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| DSP | HGNC:3052 | ENSG00000096696 | P15924 | Desmoplakin | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| DSP | Desmoplakin | A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Scaffold/PPI | 1 | 17.3× | 0.058 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| DSP | Scaffold/PPI | no | Plectin_repeat, SH3_domain, Spectrin/alpha-actinin |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| hair follicle | 1 |
| skin of hip | 1 |
| upper leg skin | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| DSP | 253 | ubiquitous | marker | skin of hip, upper leg skin, hair follicle |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| DSP | 2,897 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| DSP | P15924 | 4 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Apoptotic cleavage of cell adhesion proteins | 1 | 1038.2× | 0.006 | DSP |
| RND1 GTPase cycle | 1 | 265.6× | 0.008 | DSP |
| RND3 GTPase cycle | 1 | 259.6× | 0.008 | DSP |
| Formation of the cornified envelope | 1 | 87.8× | 0.017 | DSP |
| Keratinization | 1 | 55.7× | 0.022 | DSP |
| Neutrophil degranulation | 1 | 23.1× | 0.043 | DSP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| ventricular compact myocardium morphogenesis | 1 | 2407.4× | 0.002 | DSP |
| bundle of His cell-Purkinje myocyte adhesion involved in cell communication | 1 | 2407.4× | 0.002 | DSP |
| desmosome organization | 1 | 2106.5× | 0.002 | DSP |
| protein localization to cell-cell junction | 1 | 1872.4× | 0.002 | DSP |
| peptide cross-linking | 1 | 1404.3× | 0.002 | DSP |
| regulation of ventricular cardiac muscle cell action potential | 1 | 1404.3× | 0.002 | DSP |
| epithelial cell-cell adhesion | 1 | 1203.7× | 0.002 | DSP |
| intermediate filament cytoskeleton organization | 1 | 936.2× | 0.002 | DSP |
| adherens junction organization | 1 | 510.7× | 0.003 | DSP |
| skin development | 1 | 443.5× | 0.004 | DSP |
| regulation of heart rate by cardiac conduction | 1 | 374.5× | 0.004 | DSP |
| keratinocyte differentiation | 1 | 247.8× | 0.005 | DSP |
| intermediate filament organization | 1 | 240.7× | 0.005 | DSP |
| wound healing | 1 | 227.7× | 0.005 | DSP |
| epidermis development | 1 | 210.7× | 0.005 | DSP |
| cell-cell adhesion | 1 | 101.5× | 0.010 | DSP |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| DSP | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| DSP | 2 | Binding:2 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | DSP |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| DSP | 2 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: DSP